Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 7/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 11/20 | 0.38 |
| ▸ | F3 | P13726 | 5/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765753 | 0.91 | F2 (0.34) | F7F2F3MAPK1PRSS1 | |
| SCHEMBL23474398 | 0.89 | NTRK1 (0.44) | F7NTRK1F2F3NTRK3 | |
| SCHEMBL30765543 | 0.89 | ELANE (0.39) | NTRK1F2F3NTRK3MAPK1 | |
| SCHEMBL30765462 | 0.88 | MAPK1 (0.35) | F7F2MAPK1PRSS1HDAC6 | |
| SCHEMBL30765686 | 0.87 | F2 (0.35) | F2F3MAPK1 | |
| SCHEMBL30765495 | 0.87 | F2 (0.36) | NTRK1F2F3NTRK3MAPK1 | |
| SCHEMBL30765728 | 0.86 | MAPK1 (0.38) | F2MAPK1PRSS1 | |
| SCHEMBL23460646 | 0.85 | F7 (0.49) | F7NTRK1F2F3NTRK3 | |
| SCHEMBL30765625 | 0.85 | F2 (0.36) | F2F3MAPK1 | |
| SCHEMBL30765751 | 0.84 | F3 (0.34) | F2F3MAPK1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |